Docoh
Loading...

103 results

Filter options loading...
Top filers
Top filing types
Recent filing years
DEFA14A
PCSA Processa Pharmaceuticals Inc
20 Sep 21
Additional proxy soliciting materials
2:53pm
Statement Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement [X] Definitive Additional Materials … Soliciting Materials Pursuant to §240.14a-12 Processa Pharmaceuticals, Inc. (Name of Registrant as Specified in Its Charter) (Name of Person(s
DEF 14A
PCSA Processa Pharmaceuticals Inc
20 Sep 21
Definitive proxy
2:51pm
Statement Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials … Soliciting Materials Pursuant to §240.14a-12 Processa Pharmaceuticals, Inc. (Name of Registrant as Specified in Its Charter) (Name of Person(s) Filing Proxy
8-K
PCSA Processa Pharmaceuticals Inc
20 Sep 21
Regulation FD Disclosure
8:30am
provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 7.01. Regulation Disclosure. A copy of a slide presentation (Presentation Materials … and Exhibit 99.1. The Presentation Materials speak as of the date of this Current Report on Form 8-K. While Processa Pharmaceuticals may elect
PRE 14A
PCSA Processa Pharmaceuticals Inc
1 Sep 21
Preliminary proxy
4:46pm
Statement Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials … Soliciting Materials Pursuant to §240.14a-12 Processa Pharmaceuticals, Inc. (Name of Registrant as Specified in Its Charter) (Name of Person(s) Filing
8-K
EX-1.1
PCSA Processa Pharmaceuticals Inc
20 Aug 21
Entry into a Material Definitive Agreement
4:30pm
and biological materials or relating to the protection or restoration of the environment or human exposure to hazardous chemicals, toxic substances … or radioactive and biological materials (collectively, “Environmental Laws”). The Company neither owns nor, to its knowledge, operates any real property
10-Q
2021 Q2
PCSA Processa Pharmaceuticals Inc
12 Aug 21
Quarterly report
4:01pm
trials and disruptions in the supply chain for raw materials used in clinical trial work. Such delays could materially impact our business in future
8-K
PCSA Processa Pharmaceuticals Inc
15 Jul 21
Regulation FD Disclosure
9:54am
presentation (Presentation Materials”) that Processa Pharmaceuticals, Inc. (“Processa Pharmaceuticals”) intends to publish to its website, is attached … to this Current Report on Form 8-K and Exhibit 99.1. The Presentation Materials speak as of the date of this Current Report on Form 8-K. While Processa
8-K
EX-10.1
PCSA Processa Pharmaceuticals Inc
17 Jun 21
PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR the Development of RX-3117
11:35am
-clinical and clinical data, including pharmacology and biology data; Manufacturing documents and materials; and Manufacturing technologies) Controlled … . Such transferred materials shall include all information relevant to the Compound in the Field in the Territory in Ocuphire’s possession from Ocuphire’s
10-Q
2021 Q1
PCSA Processa Pharmaceuticals Inc
13 May 21
Quarterly report
4:30pm
such as ours, including possible delays in clinical trials and disruptions in the supply chain for raw materials used in clinical trial work
DEFA14A
PCSA Processa Pharmaceuticals Inc
26 Apr 21
Additional proxy soliciting materials
4:06pm
Statement Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement [X] Definitive Additional Materials … Soliciting Materials Pursuant to §240.14a-12 Processa Pharmaceuticals, Inc. (Name of Registrant as Specified in Its Charter) (Name of Person(s
DEF 14A
PCSA Processa Pharmaceuticals Inc
22 Apr 21
Definitive proxy
2:00pm
Statement Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [X] Definitive Proxy Statement Definitive Additional Materials … Soliciting Materials Pursuant to §240.14a-12 Processa Pharmaceuticals, Inc. (Name of Registrant as Specified in Its Charter) (Name of Person(s
10-K
2020 FY
PCSA Processa Pharmaceuticals Inc
24 Mar 21
Annual report
8:00pm
, on third party contract manufacturing organizations (CMOs), for the supply of cGMP-grade clinical trial materials and commercial quantities of our product … operations and result in lost sales. Additionally, we rely on third parties to supply the raw materials needed to manufacture our potential products. Any
D
PCSA Processa Pharmaceuticals Inc
19 Feb 21
$10.24M in equity / options, sold $10.24M, 18 investors
9:26am
to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise … and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.
8-K
EX-10.1
PCSA Processa Pharmaceuticals Inc
18 Feb 21
Processa Pharmaceuticals Announces $10.2 Million Strategic Financing
10:08am
preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such material) (the foregoing materials … (collectively, “Hazardous Materials”) into the environment, or otherwise relating to the manufacture, processing, distribution, use, treatment, storage
8-K
EX-10.2
PCSA Processa Pharmaceuticals Inc
18 Feb 21
Processa Pharmaceuticals Announces $10.2 Million Strategic Financing
10:08am
materials in accordance with this Section. (b) (i) Prepare and file with the Commission such amendments, including post-effective amendments
8-K
EX-1.1
PCSA Processa Pharmaceuticals Inc
6 Oct 20
Processa Pharmaceuticals Announces Pricing of $19.2 Million Public Offering and Uplisting to the Nasdaq Capital Market
4:05pm
and Regulations. “Time of Sale” means 7:15 PM (New York City time) on the date of this Agreement. (iii) No Other Offering Materials. The Company has … the Exchange Act. (v) Testing-the-Waters Materials. The Company (i) has not alone engaged in any Testing-the-Waters Communications, other than Testing
424B4
PCSA Processa Pharmaceuticals Inc
5 Oct 20
Prospectus supplement with pricing info
4:16pm
of a contract manufacturer could be disruptive to our operations and result in lost sales. Additionally, we rely on third parties to supply the raw materialsmaterials and reduced control over production costs, delivery schedules, reliability and quality. Any unanticipated disruption to a future contract
S-1/A
PCSA Processa Pharmaceuticals Inc
30 Sep 20
IPO registration (amended)
4:06pm
to our operations and result in lost sales. Additionally, we rely on third parties to supply the raw materials needed to manufacture our potential … products. Any reliance on suppliers may involve several risks, including a potential inability to obtain critical materials and reduced control over
S-1/A
PCSA Processa Pharmaceuticals Inc
16 Sep 20
IPO registration (amended)
8:00pm
in lost sales. Additionally, we rely on third parties to supply the raw materials needed to manufacture our potential products. Any reliance on suppliers … may involve several risks, including a potential inability to obtain critical materials and reduced control over production costs, delivery schedules
S-1/A
EX-2.1
PCSA Processa Pharmaceuticals Inc
16 Sep 20
IPO registration (amended)
8:00pm
to exploit, distribute, and derive revenue from the foregoing, and any materials or media relating to the foregoing solely in exchange for HUWX’s